Regeneron Reports 36% Year-Over-Year Revenue Growth in Q3 2026
Regeneron (REGN) reported strong third-quarter 2026 financial results, highlighted by total revenue of $5.1 billion, a 36% increase compared to the previous year. The company's growth is primarily driven by record sales from its blockbuster biologic Dupixent and the rapid market transition toward EYLEA HD, which saw U.S. net sales rise 62% to $699 million. Beyond current commercial successes, Regeneron is leveraging its proprietary genetics discovery engine to advance a promising pipeline, including an siRNA therapy for metabolic liver disease that showed significant fat reduction in early trials. Looking forward, the company plans to increase research spending by mid-teens percent in 2027 to support 15 late-stage clinical trials, supported by an established commercial infrastructure.
Topics: Biotechnology Clinical Trial Data Drug Sales Revenue Growth